Compare · CVKD vs NVO
CVKD vs NVO
Side-by-side comparison of Cadrenal Therapeutics Inc. (CVKD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVKD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 14999.0x CVKD ($12.7M).
- Over the past year, CVKD is down 71.9% and NVO is down 44.2% - NVO leads by 27.7 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 1 for CVKD).
- Company
- Cadrenal Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $4.19+1.82%
- $43.95+2.71%
- Market cap
- $12.7M
- $191.15B
- 1M return
- -23.40%
- -6.51%
- 1Y return
- -71.86%
- -44.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 8
- 8
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CVKD
- Chairman, CEO and Interim CFO Pham Quang X sold $93,294 worth of shares (22,385 units at $4.17) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 150,839 units (SEC Form 4)
- CEO and Chairman Pham Quang X sold $36,209 worth of shares (8,285 units at $4.37) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 173,224 units (SEC Form 4)
- Cadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
- CEO and Chairman Pham Quang X sold $3,075 worth of shares (652 units at $4.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 181,509 units (SEC Form 4)
- CEO and Chairman Pham Quang X sold $69,451 worth of shares (12,763 units at $5.44) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 182,161 units (SEC Form 4)
- CEO and Chairman Pham Quang X sold $6,629 worth of shares (1,165 units at $5.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.59% to 194,924 units (SEC Form 4)
- Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
- SEC Form 144 filed by Cadrenal Therapeutics Inc.
- Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care